Database providing integrated access to genome sequence, expression data and literature curation for Tuberculosis (TB) that houses genome assemblies for numerous strains of Mycobacterium tuberculosis (MTB) as well assemblies for over 20 strains related to MTB and useful for comparative analysis. TBDB stores pre- and post-publication gene-expression data from M. tuberculosis and its close relatives, including over 3000 MTB microarrays, 95 RT-PCR datasets, 2700 microarrays for human and mouse TB related experiments, and 260 arrays for Streptomyces coelicolor. (July 2010) To enable wide use of these data, TBDB provides a suite of tools for searching, browsing, analyzing, and downloading the data.

Context

Data provided by countries to WHO and estimates of TB burden generated by WHO for the Global Tuberculosis Report. TB expenditure and utilization on health services in fiscal year 2017.

https://www.who.int/tb/country/data/download/en/

Content

Acknowledgements

https://www.who.int/tb/country/data/download/en/

Photo by Morning Brew on Unsplash

Inspiration

The End TB Strategy and Covid-19 Pandemic

Doha

Multimodal Dataset of Tuberculosis Patients including CT and Clinical Case Reports

Zhankai Ye
NetID: zy172

  Dataset Summary

This dataset is curated from the original “The MultiCaRe Dataset” to focus on the chest tuberculosis patients. This is a multimodal dataset consisting of lung computed tomography (CT) imaging data and the clinical case records of tuberculosis patients, along with their case keywords, the captions of their CT images, patient_id, gender, and age… See the full description on the dataset page: https://huggingface.co/datasets/moukaii/Tuberculosis_Dataset.

TB treatments in the state of São Paulo collected between 2006 and 2016. Data were obtained through TBWEB, a system used for reporting and monitoring TB cases by the government in the state of São Paulo.

For current version see: https://data.sandiegocounty.gov/Health/2021-Tuberculosis-and-Sexually-Transmitted-Disease/atni-bxrm

Basic Metadata Tuberculosis (TB) incidence. *Rates per 100,000 population. Age-adjusted rates per 100,000 2000 US standard population.

**Blank Cells: Rates not calculated for fewer than 5 events. Rates not calculated in cases where zip code is unknown.

***API: Asian/Pacific Islander. ***AIAN: American Indian/Alaska Native.

Prepared by: County of San Diego, Health & Human Services Agency, Public Health Services, Community Health Statistics Unit, 2019.

Data Guide, Dictionary, and Codebook: https://www.sandiegocounty.gov/content/dam/sdc/hhsa/programs/phs/CHS/Community%20Profiles/Public%20Health%20Services%20Codebook_Data%20Guide_Metadata_10.2.19.xlsx

Context

This includes WHO-generated estimates of TB mortality, incidence (including disaggregation by age and sex and incidence of TB/HIV), case fatality ratio, treatment coverage (previously called case detection rate), proportion of TB cases that have rifampicin-resistant TB (RR-TB, which includes cases with multidrug-resistant TB, MDR-TB), RR/MDR-TB among notified pulmonary TB cases and latent TB infection among children aged under 5

https://www.who.int/tb/country/data/download/en/

Content

Data provided by countries to WHO and estimates of TB burden generated by WHO for the Global Tuberculosis Report.

"e_rr_in_notified_pulm","Estimates",,"Estimated number of RR-TB cases among notified pulmonary TB cases" "e_rr_in_notified_pulm_hi","Estimates",,"Estimated number of RR-TB cases among notified pulmonary TB cases: high bound" "e_rr_in_notified_pulm_lo","Estimates",,"Estimated number of RR-TB cases among notified pulmonary TB cases: low bound" "e_rr_pct_new","Estimates",,"Estimated percentage of new TB cases with rifampicin resistant TB" "e_rr_pct_new_hi","Estimates",,"Estimated percentage of new TB cases with rifampicin resistant TB: high bound" "e_rr_pct_new_lo","Estimates",,"Estimated percentage of new TB cases with rifampicin resistant TB: low bound" "e_rr_pct_ret","Estimates",,"Estimated percentage of previously treated TB cases with rifampicin resistant TB" "e_rr_pct_ret_hi","Estimates",,"Estimated percentage of previously treated TB cases with rifampicin resistant TB: high bound" "e_rr_pct_ret_lo","Estimates",,"Estimated percentage of previously treated TB cases with rifampicin resistant TB: low bound" "e_tbhiv_prct","Estimates",,"Estimated HIV in incident TB (percent)" "e_tbhiv_prct_hi","Estimates",,"Estimated HIV in incident TB (percent), high bound" "e_tbhiv_prct_lo","Estimates",,"Estimated HIV in incident TB (percent), low bound

https://gitlab.procc.fiocruz.br/oswaldo/DS_2017/blob/4e8f97ebbd15bdba60c2e3c0d91298a24801a2c5/exemplos/TB_data_dictionary_2017-10-23.csv

Acknowledgements

https://www.who.int/tb/country/data/download/en/

Inspiration

The End TB strategy.

This dataset includes two tables on tuberculosis (TB) in California: 1) TB cases and rates by place of birth, sex, age and race/ethnicity 2) TB cases by local health jurisdiction (LHJ). TB case reports are submitted to the California Department of Public Health (CDPH), TB Control Branch (TBCB), by 61 local health jurisdictions (58 counties, and the cities of Berkeley, Long Beach, and Pasadena).

Tuberculosis Therapeutics Market Outlook

The global tuberculosis therapeutics market size was valued at USD 1.8 billion in 2023 and is projected to reach USD 3.5 billion by 2032, growing at a compound annual growth rate (CAGR) of 7.2% during the forecast period. The significant growth in the market can be attributed to increased awareness about tuberculosis (TB), advancements in diagnostic technologies, and heightened government initiatives for TB eradication. Moreover, the rise in drug-resistant TB cases necessitates the development of new and effective therapeutic options, fuelling market growth.

The primary growth factor driving the tuberculosis therapeutics market is the alarming rise in the incidence of TB worldwide. According to the World Health Organization (WHO), TB is one of the top 10 causes of death globally, with millions of new cases reported annually. The WHO's End TB Strategy aims to reduce TB deaths by 90% and cut new cases by 80% between 2015 and 2030. This has led to increased funding and research initiatives to develop effective TB drugs and treatment protocols, thereby propelling market growth. Additionally, the emergence of multi-drug-resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-TB) has intensified the need for novel therapeutics.

Another significant growth driver is the increasing government and non-governmental organization (NGO) interventions and funding for TB control programs. Governments across the globe are implementing national TB programs, supported by organizations like the Global Fund to Fight AIDS, Tuberculosis, and Malaria, which provide substantial funding for TB diagnostics and treatments. These initiatives not only enhance the accessibility and affordability of TB therapeutics but also spur the demand for advanced drug formulations and combinations, contributing to market expansion. Furthermore, strategic collaborations between pharmaceutical companies and research institutions are fostering the development of innovative TB drugs.

Technological advancements in the field of diagnostics are also contributing to the growth of the tuberculosis therapeutics market. The introduction of rapid diagnostic tests, such as GeneXpert and TB-LAMP, has significantly improved the speed and accuracy of TB diagnosis, enabling timely initiation of treatment. Improved diagnostic capabilities help in identifying drug-resistant strains more efficiently, leading to better-targeted treatment regimens. Moreover, the integration of digital health technologies, such as mobile health (mHealth) applications, is enhancing patient adherence to TB treatment, thereby improving treatment outcomes and driving market growth.

The regional outlook for the tuberculosis therapeutics market indicates significant growth opportunities across various geographies. Asia Pacific holds the largest market share due to the high burden of TB in countries like India, China, and Indonesia. North America and Europe are also anticipated to witness substantial growth, driven by increased research funding and the presence of major pharmaceutical companies. The Middle East and Africa region, with its high TB prevalence rates, is expected to see growth supported by international aid and government initiatives. Latin America is projected to show moderate growth, with efforts to strengthen healthcare infrastructure and TB control programs.

Drug Class Analysis

The tuberculosis therapeutics market is segmented by drug class into first-line drugs, second-line drugs, and combination drugs. First-line drugs, including isoniazid, rifampicin, ethambutol, and pyrazinamide, have been the cornerstone of TB treatment for decades. These drugs are highly effective against Mycobacterium tuberculosis and are recommended for treating drug-susceptible TB. Despite their efficacy, the emergence of drug-resistant TB strains has posed significant challenges, leading to increased focus on second-line and combination drugs. First-line drugs continue to dominate the market due to their widespread use and cost-effectiveness, especially in high-burden regions.

Second-line drugs, such as fluoroquinolones and injectable agents like amikacin, are used to treat MDR-TB and XDR-TB cases. The demand for second-line drugs is rising due to the growing incidence of drug-resistant TB, which cannot be effectively treated with first-line drugs. These drugs are often more expensive and have more severe side effects, but they are crucial for managing res

This dataset described the entire number of adult holy water sites (HWS) attendees (≥18 years of age) who were screened for Pulmonary Tuberculosis (PTB) -suggestive symptoms at nine selected study zones (HWS) found across the study region. During the study period, a total of 10,313 adult HWS (≥ 18 years of age) were screened, and 560 individuals were PTB symptomatic and participated. Out of 560 PTB symptomatic HWS attendees who participated, 122 (21.8%) were Lowenstein- Jensen (LJ) culture-positive (bacteriologically confirmed cases). Their sociodemographic characteristics and PTB infection risk factors are detailed. All LJ culture-positive isolates were subjected to spoligotyping, resulting in 116 isolates with interpretable spoligo-patterns. We performed drug susceptibility testing for all 122 (LJ culture)-positive isolates using MTBDRplus v2 and MTBDRsl v2 line probe assays.
Drug-susceptibility testing (DST) results for first and second line anti-TB drugs are detailed in this dataset. Furthermore, a prospective follow-up study on 438 PTB-symptomatic individuals with culture-negative test results was done to determine the prevalence of developing active TB disease subsequent to residing at a HWS. The duration of follow-up was 12 months, starting on the date that a negative culture result was obtained. Thus, 30 (6.8%) were infected with TB and developed active TB disease post-exposure to HWS. In general, in these attached datasets, details of the study participants, LJ culture-testing results, DST results, as well as genotyping findings of the isolates are illustrated.

In 2023, there were around 1.09 million deaths due to tuberculosis among HIV-negative people worldwide. In addition, there were 160,000 deaths due to tuberculosis among people who were HIV-positive. This statistic shows the number of tuberculosis deaths worldwide from 2010 to 2023, by HIV status.

WHO_TB_Incidence

Tuberculosis (TB) Detection Market Outlook

The global Tuberculosis (TB) Detection market size was valued at USD 2.5 billion in 2023 and is projected to reach approximately USD 4.7 billion by 2032, growing at a CAGR of 7.5% during the forecast period. The increasing prevalence of TB, along with advancing diagnostic technologies, are primary growth factors contributing to this robust market expansion.

The rise in TB prevalence is a significant growth driver for the TB detection market. According to the World Health Organization (WHO), TB remains one of the top 10 causes of death worldwide. The high incidence rates in developing countries, along with the rise of multidrug-resistant TB strains, necessitate the development of efficient and rapid diagnostic methods. Governments and international health organizations are investing heavily in TB control programs, further driving the demand for advanced TB diagnostic tools.

Technological advancements in diagnostic tools also play a crucial role in market growth. The development of innovative diagnostic tests, such as nucleic acid amplification tests (NAATs) and culture-based tests, has significantly improved the accuracy and speed of TB detection. These technologies enable healthcare providers to diagnose TB more efficiently and initiate timely treatment, thereby improving patient outcomes. Continuous R&D efforts are expected to yield even more advanced diagnostic solutions in the coming years, further propelling market growth.

Increasing awareness and early detection campaigns are other vital contributors to market expansion. Public health initiatives aimed at educating people about TB symptoms and the importance of early detection are helping to reduce the spread of the disease. These campaigns, coupled with improved access to healthcare facilities and diagnostic services, are instrumental in increasing the adoption of TB detection tests across various regions.

Regionally, the Asia Pacific is expected to dominate the TB detection market due to the high burden of TB cases in countries like India and China. Government initiatives and international collaborations aimed at TB control are significant growth drivers in this region. North America and Europe are also anticipated to witness substantial growth, driven by advanced healthcare infrastructure and increasing R&D investments.

Test Type Analysis

The TB detection market is segmented by test type, which includes Smear Microscopy, Culture-Based Tests, Nucleic Acid Amplification Tests, Mantoux Test, Serological Tests, and others. Smear microscopy has been the traditional method for TB detection due to its simplicity and cost-effectiveness. Despite its limitations in sensitivity and specificity, it remains widely used, particularly in resource-limited settings. The ease of conducting smear microscopy without the need for advanced laboratory facilities makes it a crucial tool in high-burden areas.

Culture-based tests are considered the gold standard for TB diagnosis due to their high specificity. These tests involve cultivating Mycobacterium tuberculosis from patient samples, which provides definitive evidence of TB infection. However, the lengthy time required to obtain results and the need for specialized laboratory infrastructure limit their use primarily to well-equipped diagnostic centers. Advances in automated culture systems aim to reduce turnaround times, enhancing their utility in clinical settings.

Nucleic Acid Amplification Tests (NAATs) represent one of the most significant technological advancements in TB diagnostics. These tests amplify the genetic material of Mycobacterium tuberculosis, allowing for rapid and highly sensitive detection. NAATs can provide results within hours, enabling prompt initiation of treatment. The high cost and need for sophisticated equipment, however, remain challenges for widespread adoption, particularly in low-resource settings.

The Mantoux test, or tuberculin skin test, is used to determine if a person has been exposed to TB bacteria. This test involves injecting a small amount of tuberculin into the skin and observing the reaction after 48-72 hours. While useful for screening purposes, the Mantoux test cannot distinguish between latent and active TB and is subject to false-positive results due to prior Bacillus Calmette-Guérin (BCG) vaccination or non-tuberculosis mycobacterial infections.

Serological tests, which detect antibodies against TB bacteria in the blood, have largely fallen out of favor du

United States US: Incidence of Tuberculosis: per 100,000 People data was reported at 3.100 Ratio in 2016. This records a decrease from the previous number of 3.300 Ratio for 2015. United States US: Incidence of Tuberculosis: per 100,000 People data is updated yearly, averaging 4.900 Ratio from Dec 2000 (Median) to 2016, with 17 observations. The data reached an all-time high of 6.700 Ratio in 2000 and a record low of 3.100 Ratio in 2016. United States US: Incidence of Tuberculosis: per 100,000 People data remains active status in CEIC and is reported by World Bank. The data is categorized under Global Database’s United States – Table US.World Bank.WDI: Health Statistics. Incidence of tuberculosis is the estimated number of new and relapse tuberculosis cases arising in a given year, expressed as the rate per 100,000 population. All forms of TB are included, including cases in people living with HIV. Estimates for all years are recalculated as new information becomes available and techniques are refined, so they may differ from those published previously.; ; World Health Organization, Global Tuberculosis Report.; Weighted average;

The Online Tuberculosis Information System (OTIS) on CDC WONDER contains information on verified tuberculosis (TB) cases reported to the Centers for Disease Control and Prevention (CDC) by state health departments, the District of Columbia and Puerto Rico since 1993. These data were extracted from the CDC national TB surveillance system. OTIS reports case counts, incidence rates, population counts, percentage of cases that completed therapy within 1 year of diagnosis, and percentage of cases tested for drug susceptibility. Data for 22 variables are included in the data set, including: age groups, race / ethnicity, sex, vital status, year reported, state, metropolitan area, several patient risk factors, directly observed therapy, disease verification criteria and multi-drug resistant TB. Each year these data are updated with an additional year of cases plus revisions to cases reported in previous years. OTIS is produced by the U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention (CDC), National Center for HIV/AIDS, viral Hepatitis, STD and TB Prevention (NCHHSTP).

Tuberculosis is a communicable chronic disease and one of the top ten causes of death worldwide according to World Health Organization (WHO). With availability of clean and well encoded clinical data from tuberculosis patients, artificial intelligence and machine learning algorithms would be able to transform the management of tuberculosis patients through intelligent prediction and intervention. This dataset contains four hundred and thirty (430) clinical data from patients with tuberculosis at Tuberculosis and Leprosy Hospital, Eku, Delta State, Nigeria. The dataset was gathered through validated and structured questionnaire administered using random sampling after obtaining the patients' consent. The collated dataset was pre-processed and encoded with variables (features) for prediction which include cough, night sweat, breathing difficulty, fever, chest pain, sputum, immune suppression, loss of pleasure, chill, lack of concentration, irritation, loss of appetite, loss of energy, lymph node enlargement, systolic blood pressure and BMI. Prediction of tuberculosis based on the clinical data from patients' features would play an essential role in diagnosis, intervention and management of tuberculosis patient.

This dataset provides annual data on paediatric TB patients notified, first reported in the 2020 TB report. The notification is based on the diagnosing Primary Health Institution (PHI), meaning it reflects the cases initially recorded at the diagnosing facility. It also contains details of net paediatric TB patients notified (since 2021 report) based on the current PHI rather than the diagnosing facility. Unlike gross notifications, this dataset accounts for patient movement, meaning it includes only those TB patients currently in the facility, district, or state after adjustments for transfers in and out. The number of paediatric TB patients who have started treatment after notificatiion has also been captured in the dataset (started in 2021 report).

This study focused on describing and quantifying the steps in the tuberculosis (TB) prevention cascade of care within health department clinics. This included better understanding the proportions of patients with latent TB infection who are identified, offered treatment, accept treatment, and complete treatment.

The global tuberculosis treatment market reached a value of about USD 1.74 Billion in 2024. The market is expected to grow at a CAGR of 7.57% during the forecast period of 2025-2034 to attain a value of USD 3.61 Billion by 2034. The growth of the market is driven by the rising favourable government policies to increase demand for tuberculosis (TB) diagnostics.

Data calculated for the State of the Tropics 2014 Report using existing data source: WHO Global TB Database ('WHO TB Burden Estimates') at http://www.who.int/tb/country/global_tb_database/en/;